STAT

Why a growing number of women with breast cancer are choosing double mastectomy

Even as cancer treatments have become increasingly targeted, a growing number of women with cancer in one breast are opting for a double mastectomy.

Three years ago, Crystal Collum was 37 years old with three kids at home, “kind of just trucking through life” in Columbia, S.C., when she felt a lump on her breast while showering. She didn’t hesitate — she’d watched her best friend go through breast cancer years earlier, and she knew what to do. Within three weeks she was starting chemotherapy.

But soon after, she was confronted with a choice that even she was unprepared for: have a lumpectomy, a targeted surgery that removes only the tumor, or have a double mastectomy — surgery to completely remove both breasts. The decision was an agonizing one.

“I really could not think about anything else. I really couldn’t. It consumed me,” Collum recalled. “There’s so many things during this process that you have no control over, and then the biggest decision of the entire thing is kind of dropped in your lap and you’re like, no, I don’t feel like I should be making this decision.”

After weeks of soul-searching, information-gathering, talking to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks